Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

ClinicalTrials.gov ID: NCT00262522

Public ClinicalTrials.gov record NCT00262522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects

Study identification

NCT ID
NCT00262522
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Abbott
Industry
Enrollment
664 participants

Conditions and interventions

Interventions

  • lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2005
Primary completion
Jun 30, 2008
Completion
Jun 30, 2008
Last update posted
Feb 5, 2012

2005 – 2008

United States locations

U.S. sites
30
U.S. states
13
U.S. cities
26
Facility City State ZIP Site status
Site Reference ID/Investigator# 823 Phoenix Arizona 85006
Site Reference ID/Investigator# 846 Phoenix Arizona 85012
Site Reference ID/Investigator# 851 Beverly Hills California 90211
Site Reference ID/Investigator# 872 Fountain Valley California 92708
Site Reference ID/Investigator# 826 Long Beach California 90813
Site Reference ID/Investigator# 876 Newport Beach California 92663
Site Reference ID/Investigator# 875 Washington D.C. District of Columbia 20037
Site Reference ID/Investigator# 870 Atlantis Florida 33462
Site Reference ID/Investigator# 844 Fort Lauderdale Florida 33311
Site Reference ID/Investigator# 874 Miami Florida 33136
Site Reference ID/Investigator# 1153 Orlando Florida 32803
Site Reference ID/Investigator# 827 Orlando Florida 32803
Site Reference ID/Investigator# 783 Plantation Florida 33317
Site Reference ID/Investigator# 877 Port Saint Lucie Florida 34952
Site Reference ID/Investigator# 845 Safety Harbor Florida 34695
Site Reference ID/Investigator# 849 Sarasota Florida 34243
Site Reference ID/Investigator# 825 Tampa Florida 33614
Site Reference ID/Investigator# 848 Atlanta Georgia 30309
Site Reference ID/Investigator# 873 Macon Georgia 31201
Site Reference ID/Investigator# 1154 Chicago Illinois 60612
Site Reference ID/Investigator# 824 Chicago Illinois 60613
Site Reference ID/Investigator# 792 Wichita Kansas 67214
Site Reference ID/Investigator# 1157 Minneapolis Minnesota 55404
Site Reference ID/Investigator# 871 St Louis Missouri 63108
Site Reference ID/Investigator# 2450 Rochester New York 14620
Site Reference ID/Investigator# 784 Charlotte North Carolina 28209
Site Reference ID/Investigator# 1155 Dallas Texas 75208
Site Reference ID/Investigator# 850 Dallas Texas 75246
Site Reference ID/Investigator# 843 Houston Texas 77004
Site Reference ID/Investigator# 1156 Hampton Virginia 23666

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00262522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2012 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00262522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →